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Macaquesy methods for cellular immunotherapies are needed. We assessed ex vivo pulsing
of overlapping SIV Gag 15mer peptides onto either whole blood or PBMC in 15 randomly assigned SIV-
infected macaques. Both delivery methods were safe and immunogenic, stimulating high levels of broad and
polyfunctional Gag-speciﬁc CD4 and CD8 T cells. Delivery of overlapping Gag peptides via either whole blood
or PBMC is suitable for clinical evaluation.
© 2008 Elsevier Inc. All rights reserved.IntroductionPractical and effective HIV immunotherapies are needed not
requiring ex vivo manipulation of specialized blood cells (Lu et al.,
2003). Intravenous re-infusion of fresh autologous peripheral blood
mononuclear cells (PBMC) or whole blood (WB) pulsed with over-
lapping SIV peptides (termed “OPAL”) has been highly immunogenic
in early pilot studies (Chea et al., 2005) and, when delivered onto
PBMC, effective in reducing viral load and delaying SIV-induced AIDS
in monkeys (De Rose et al., 2008). However, delivery of peptides via
whole blood has not been compared for immunogenicity head-to-
head with delivery of peptides via PBMC. If similarly immunogenic,
pulsing WB is far preferred as a delivery method since no laboratory
separation of PBMC is required, permitting a bedside technique that
would be much more widely available to HIV-infected people.
Results
To compare the immunogenicity of peptide-pulsed whole blood
with peptide-pulsed PBMC, we studied the 20 animals remaining from
a previous immunotherapy trial (De Rose et al., 2008). In the prior
study, 32 pigtail macaques were infected with SIVmac251 and then
vaccinated with SIV Gag peptides (Gag, n=10), peptides spanning alll rights reserved.SIV proteins (All, n=11) or control (n=11) (De Rose et al., 2008). The
immunotherapy resulted in high levels of SIV-speciﬁc CD4 and CD8 T
cells, a 10-fold reduction in SIV viral load in both the Gag and All
groups and delayed progression to AIDS-related mortality (De Rose
et al., 2008).
Sixty-four weeks after SIV infection, all 15 remaining, previously
immunized, SIV-infected macaques were re-randomized (8:7) to
receive 3 doses of 125 overlapping SIV Gag 15mer peptides (10 μg/
ml) pulsed for 1 h at 37 °C onto either heparin-anticoagulated WB
(9 ml) or PBMC (derived from 9 ml blood, in 0.5 ml saline) (Chea et al.,
2005; De Rose et al., 2008). The animals were stratiﬁed based on prior
immunizations, baseline VL, CD4 T cells, Mane-A⁎10 status and Gag-
speciﬁc T-cell responses (Table 1). The 5 animals remaining from the
control group were followed but not re-immunized.
OPAL immunization using Gag peptides pulsed onto PBMC or WB
was safe with no differences between the arms in body weight or
hematology proﬁles (not shown). The OPAL vaccinations, with both
WB and PBMC, stimulated considerable Gag-speciﬁc CD4 and CD8 T-
cell immunity. Similar levels of T-cell immunity were induced by the
two vaccination methods (Figs. 1A, B, PN0.2, 2-sided t-tests, for all
comparisons). Gag-speciﬁc CD4 T-cell responses in the PBMC group
rose by a mean of 2.29% 4 weeks after the ﬁrst vaccination and 1.96%
7 weeks after the ﬁrst vaccination, compared to 1.94% and 0.98%
respectively in theWB group. For the Gag-speciﬁc CD8 T-cell response
there was a 1.89% and 1.53% mean rise in response in the PBMC group
4 and 7 weeks after the initial vaccination respectively and 1.24% and
0.78% rise in the WB group respectively. Gag-speciﬁc CD4 T-cell
Table 1
Baseline characteristics of macaques
Group Macaque
ID
Mane-A⁎10
status
Prior
immunizationsa
VL week 0b
(log10 copies/ml)
CD4 T cells
week 0 (% CD4+
T lymphocytes)
Control 6169 Negative None 5.89 24.5
8014 Positive None 6.05 22.2
9017 Positive None 3.29 36.6
9176 Positive None 3.34 33.3
9183 Positive None 6.14 23.2
Mean of group 4.94 28.0
SE 0.67 2.9
PBMC 1.3731 Positive All 3.87 35.5
6804 Negative Gag 4.45 19.6
8244 Positive Gag 5.34 22.8
8673 Negative Gag 3.11 33.3
8682 Negative All 4.54 36.9
9021 Positive All 5.12 28.8
9175 Positive All 5.36 22.7
9196 Negative Gag 4.46 15.2
Mean of group 4.53 26.9
SE 0.27 2.8
WB 8020 Positive Gag 6.29 23.0
8240 Positive All 3.19 27.0
8251 Negative All 5.83 20.2
8454 Positive Gag 3.11 27.7
8680 Negative All 5.75 22.4
8873 Negative Gag 3.21 28.9
9020 Positive All 3.11 38.6
Mean of group 4.36 26.8
SE 0.57 2.3
a Week 0 = ﬁrst WB vs PBMC vaccination, which was week 64 after SIV infection.
b Immunized animals previously received either Gag or All SIV peptides pulsed onto
PBMC at weeks 4, 6, 8, 10, 36, 39, and 42 after SIV infection.
202 Rapid Communicationresponses rose N0.5% in 6 of the 8 PBMC vaccinated animals compared
to 3 of the 7WB-immunized animals. Gag-speciﬁc CD8 responses rose
N0.5% in 4 of 8 animals in the PBMC group and 4 of 7 in theWB group.
There was no rise in CD4 or CD8 T-cell responses in the Control group.
Since the animals had been previously immunized with OPAL
vaccinations, we were able to compare the effect of this set of
immunizations with those administered previously. The rises in Gag-
speciﬁc CD4 and CD8 T-cell responses were similar to that observed
with the prior Gag-based immunotherapywith PBMC, even in animals
previously receiving peptides spanning all SIV proteins, which initially
blunted the Gag-speciﬁc T-cell responses (Fig 1C, D).
The breadth of the Gag-speciﬁc T-cell immunity was studied by
analyzing responses to 5 subpools of 25 Gag 15mer peptides at week 0,
4 and 7 and determining whether a rise of ≥0.1% of CD4 or CD8 T cells
after vaccination occurred. For Gag-speciﬁc CD4 T-cell responses, a
mean of 2.14 (range 0–4) of the 5 pools were stimulated in WB-
immunized animals compared to 2.37 (0–5) pools in the PBMC
immunized group. For Gag-speciﬁc CD8 T-cell responses, a mean of
1.71 pools were stimulated in theWB group (0–5) compared to 2.00 in
the PBMC group (0–5). There were no signiﬁcant rises in SIV-speciﬁc
CD4 or CD8 T-cell responses in the 5 control animals.
Increasing evidence suggests that T cells which express multiple
effector molecules (“polyfunctional” T cells) are most effective in
controlling virus replication (Betts et al., 2006). We therefore analyzed
the SIV Gag-speciﬁc T cells for expression of TNFα, MIP1β,IL-2 and the
degranulation marker CD107a. Multiple effector molecules were
expressed by Gag-speciﬁc T lymphocytes, although the expression of
IL-2 was low, consistent with the long duration of infection and active
viral replication prior to this study. There were no signiﬁcant differ-
ences in the expression of the various molecules between the 2
delivery methods (Fig. 2).
This study immunized animals with partial control of viremia due
to prior immunizations (De Rose et al., 2008). No further reductions in
mean plasma viremia or changes in CD4 T cells occurred during the
course of this re-boosting protocol (Fig. 3A). This likely reﬂects thelong duration of SIV infection prior to this study, and lack of
antiretroviral cover during the immunization process (De Rose et al.,
2008). Using a last-observation-carried-forward analysis to account
for missing data (De Rose et al., 2008), a signiﬁcant difference
(p=0.027, 2 sided t-test of time weighted area-under-the-curve VL
weeks 12–73) in viremia was maintained between controls and
vaccinated animals during this protocol (Fig 3B).
We previously observed that the immunogenicity of peptide-pulsed
blood cells in macaques was inversely proportional to VL (Chea et al.,
2005). In a post-hoc analysis, the non-signiﬁcantly lower immunogeni-
cityof theWBgroupwasexploredbyexamining the animals thatdidnot
mount Gag-speciﬁc CD4 or CD8 T-cell responses to the immunotherapy.
Although the PBMC and WB groups were matched for mean (±SE) VL
(4.53±0.27 vs 4.36±0.57 log10 copies/ml respectively, Table 1) at the
start of this study, the WB group had a larger upper range of pre-
treatment VLs. The 3 animals in theWB-immunized group that failed to
generate a signiﬁcant T-cell response had the highest baseline VLs of all
15 immunized animals (5.75–6.29 log10 copies/ml, Table 1) and had
experienced some CD4 T-cell depletion (all to b15% of total lympho-
cytes) by the end of the study. The other 4 WB vaccinated animals
(baseline viral loads all ≤3.2 log10 copies/ml) all had signiﬁcant rises in
Gag-speciﬁc CD4 or CD8 T cells. Our results suggest that initial clinical
trials should occur in subjectswithwell-controlled viremia, for example
during antiretroviral therapy.
Discussion
Immunotherapy with overlapping Gag peptides delivered brieﬂy
onto either fresh WB or PBMC ex vivo for 1 h stimulated high levels of
CD4 and CD8 T-cell immunity in SIV-infected animals. Gag-speciﬁc
responses of over 10% of all CD4 or CD8 T cells were induced in some
animals. There was no signiﬁcant difference in the immunogenicity of
OPAL immunotherapy delivered by either WB or PBMC.
The T cells induced by the OPAL immunotherapy in both the PBMC
andWB groups had similar breadth (approximately 2 of 5 pools of Gag
peptides recognised). There was no signiﬁcant positive or negative
relationship between the breadth and strength of T-cell immunity in
this study (not shown) as observed following our original vaccinations
(De Rose et al., 2008). Such a relationship may have been obscured
either by the lower numbers of animals or the effect of prior
immunizations. There was similar functionality of the SIV-speciﬁc T
cells as assessed by expression of up to 5 effector molecules. Minimal
T-cell responses were detectable in the control group of 5 animals.
This study began just over 1 year after the animals ﬁrst came off
antiretroviral treatment (FTC and tenofovir). A signiﬁcant difference in
virologic control was maintained between treated and control groups
during this extended period, although no further reductions in virus
levels occurred during this study. There are limitations in interpreting
this data, however, since 12 animals were euthanized prior to this
study. However, this data does suggest that the virologic effect of OPAL
immunotherapy can be durable.
The T-cell immunogenicity of Gag peptides pulsed onto either WB
or PBMC is comparable or superior to more complex dendritic cell-
based immunotherapies (Lu et al., 2003) and exceeds those generally
obtainable with DNA of viral vector approaches (Hel et al., 2000;
Lisziewicz et al., 2005; von Gegerfelt et al., 2007). Overall, our data
support moving WB and PBMC delivery approaches of peptide
immunotherapy vigorously into clinical trials.
Materials and methods
Animals
Juvenile pigtail macaques (Macaca nemestrina) free from Simian
retrovirus type D were studied in protocols approved by institutional
animal ethics committees and cared for in accordance with Australian
Fig. 2. Expression of multiple effector molecules by Gag-speciﬁc CD8 and CD4 T
lymphocytes. Fresh blood obtained 3 weeks after the last vaccination from all animals
was stimulated with overlapping Gag 15mer peptides and expression of IFNγ, TNFα,
MIP1β, and CD107a studied on gated CD8β+ and CD8β− lymphocytes by ﬂow cytometry.
Mean levels of total Gag-speciﬁc expression of all effector molecules in each group are
shown.
Fig. 1. OPAL immunotherapy with whole blood or PBMC. Fifteen SIV-infected pigtail macaques received overlapping SIV Gag 15mer peptides pulsed onto either PBMC or whole blood
3 times over 4 weeks and were compared to 5 controls. A, B. Percent Gag-speciﬁc CD4+ and CD8+ T lymphocytes expressing IFNγ over time after WB or PBMC-based vaccinations.
Mean (±SE) responses are shown. Vaccinations are shownwith arrows. C, D. Gag-speciﬁc CD4+ and CD8+ T cells expressing IFNγ over time based on initial vaccination status (Gag or
All SIV peptides).
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macaques were typed for MHC class I alleles by reference strand
mediated conformational analysis and the presence of Mane-A⁎10
conﬁrmed by sequence speciﬁc primer PCR as described (Pratt et al.,
2006; Smith et al., 2005b). 36 macaques were injected intravenously
with 40 tissue culture infectious doses of SIVmac251 (kindly provided
by R. Pal, Advanced Biosciences, Kensington, MD) as described
previously (Batten et al., 2006; Smith et al., 2005a) and randomized
into 3 groups of 12 animals (OPAL-Gag, OPAL-All, Controls) 3 weeks
later. Animals received subcutaneous injections of dual antiretroviral
therapy with tenofovir and emtricitibine (kindly donated by Gilead,
Foster City, CA; both 30 mg/kg/animal) for 7 weeks from week 3 (Hel
et al., 2000; Lisziewicz et al., 2005; Lori et al., 2000; Shen et al., 2003;
Villinger et al., 2002).
Immunizations
In the earlier study, two animal groups (OPAL-Gag and OPAL-All)
were immunized with OPAL immunotherapy using PBMC derived
from 18 ml blood at weeks 4, 6, 8, 10, 36, 39 and 42 as previously
described (Chea et al., 2005; De Rose et al., 2008). In the current study,
we re-randomized the remaining 15 previously vaccinated animals to
receive Gag peptides pulsed onto PBMC derived from 9 ml of whole
blood or onto 9 ml of fresh whole blood. The 15 monkeys were
stratiﬁed based on VL, CD4 T cells, Gag-speciﬁc CD4 and CD8 T-cell
immunity, Mane-A⁎10 status (Smith et al., 2005a) and prior OPAL
immunotherapy (Gag or All) to match the groups as evenly as possible
(Table 1). Brieﬂy, PBMC were isolated over Ficoll-paque from 9 ml of
blood (anticoagulated with Na+-heparin). All isolated PBMC were
suspended in 0.5 ml of normal saline. The 125 SIVmac239 Gag were
added to the 9 ml blood or 0.5 ml of PBMC at 10 μg/ml of each peptide
within the pool. Peptides were 15mers overlapping by 11 amino acids
Fig. 3. Viral Loads. A. Mean (±SE) viral load from week 64, the time of the ﬁrst WB or
PBMC boost is shown across the vaccine groups. B. SIV viral load over time. Animals that
controlled SIV viral load on the initial ART therapy are shown. A last-observation-
carried-forward analysis was used for animals euthanized with incipient AIDS.
204 Rapid Communicationat N80% purity kindly provided by the NIH AIDS reagent repository
program. To pool the peptides, each 1 mg vial of lyophilised 15mer
peptide was solubilized in 10–50 μl of pure DMSO and added together.
The concentration of the SIV Gag peptide pool was 629 μg/ml/peptide.
The peptide-pulsed PBMC were held for 1 h in a 37 °C waterbath,
gently vortexed every 15 min and then, without washing, re-infused
IV into the autologous animal. The 5 control macaques did not receive
vaccine treatment.
Immunology assays
SIV-speciﬁc CD4 andCD8 T-cell immune responseswere analyzed by
expression of intracellular IFNγ as previously described (De Rose et al.,
2007). Brieﬂy, 200 μl whole blood was incubated at 37 °C with 1 μg/ml/
peptide overlapping 15mer SIV Gag peptide pool (described above) or
DMSO alone and the co-stimulatory antibodies anti-CD28 and anti-
CD49d (BD Biosciences/Pharmingen San Diego CA) and Brefeldin A
(10 μg/ml, Sigma) for 6 h. Anti-CD3-PE, anti-CD4-FITC and anti-CD8-
PerCP (BD, clones SP34, M-T477 and SK1 respectively) antibodies were
added for 30 min. Red blood cells were lysed (FACS lysing solution, BD)
and the remaining leukocyteswere permeabilized (FACS Permeabilizing
Solution 2, BD) and incubatedwith anti-human IFNγ-APC antibody (BD,
clone B27) prior toﬁxation and acquisition (LSRII, BD). The percentage of
antigen-speciﬁc gated lymphocytes expressing IFNγ was assessed in
both CD3+CD4+ and CD3+CD8+ lymphocyte subsets. To assess the
expression ofmultiple effectormolecules,we performed a simultaneous
analysis of IFNγ, TNFα, MIPIβ, IL-2 and CD107a expressions on CD8β+
and CD8β− lymphocytes at week 7 after the initial vaccination as
previously described (Betts et al., 2005; Betts et al., 2006).Virology assays
Plasma SIV RNA was quantitated by real time PCR on 140 μl of
plasma at the University of Melbourne (lower limit of quantitation 3.1
log10 copies/ml) at all time-points using a TaqMan probe as previously
described (Dale et al., 2002; De Rose et al., 2007).
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